Macrocyclic deaza-purinones for the treatment of viral infections

1. A compound having formula (I)

and pharmaceutically accepted salts thereof, wherein

n is 1 or 2;

X is O or NH;

Y is an aromatic ring optionally substituted with one or more substituents each independently selected from the group consisting of C 1-4 alkoxy and halogen; and

Z is selected from the group consisting of C 1-10 alkyl, C 1-6 alkyl-NH—C(O)—C 1-6 alkyl, C 1-6 alkyl-NH—, C 1-6 alkyl-NH—C(O)—C 1-6 alkyl-O—, C 1-10 alkyl-O—, C 1-6 alkyl-O—C 1-6 alkyl-, and C 1-6 alkyl-O—C 1-6 alkyl-O—, wherein said alkyl is saturated or unsaturated, and wherein said alkyl is optionally substituted with an alkyl or alkylhydroxyl.

2. The compound of claim 1 , wherein X is O.

3. The compound of claim 1 , wherein X is NH.

4. The compound of claim 1 , wherein Y is phenyl optionally substituted with methoxy or fluorine.

5. The compound of claim 1 , wherein Y is pyridinyl.

6. The compound of claim 1 , wherein Z is C 1-10 alkyl, and wherein said alkyl is saturated or unsaturated.

7. The compound of claim 1 , wherein Z is C 1-6 alkyl-NH—, and wherein said alkyl is saturated or unsaturated.

8. The compound of claim 1 , wherein Z is C 1-10 alkyl-O—, and wherein said alkyl is saturated or unsaturated.

9. The compound of claim 1 wherein;

n is 1 or 2;

X is O or NH; and

Y is an aromatic ring optionally substituted with one or more substituents each independently selected from the group consisting of C 1-4 alkoxy and halogen.

10. The compound of claim 1 , wherein

n is 1 or 2;

X is O or NH;

Y is an aromatic ring optionally substituted with one or more substituents each independently selected from the group consisting of C 1-4 alkoxy and halogen; and

Z is selected from the group consisting of C 1-10 alkyl, C 1-6 alkyl-NH—, and C 1-10 alkyl-O—, and wherein said alkyl is saturated or unsaturated.

11. The compound of claim 1 , wherein

n is 1 or 2;

X is O or NH;

Y is an aromatic ring optionally substituted with one or more substituents each independently selected from the group consisting of C 1-4 alkoxy and halogen; and

Z is C 1-10 alkyl, wherein said alkyl is saturated or unsaturated.

12. The compound of claim 1 , wherein

n is 1 or 2;

X is O or NH;

Y is an aromatic ring optionally substituted with one or more substituents each independently selected from the group consisting of C 1-4 alkoxy and halogen; and

Z is C 1-10 alkyl-O—, wherein said alkyl is saturated or unsaturated.

13. The compound of claim 1 , wherein

n is 1;

X is O;

Y is an aromatic ring optionally substituted with one or more substituents each independently selected from the group consisting of C 1-4 alkoxy and halogen; and

Z is C 1-6 alkyl-NH—, wherein said alkyl is saturated or unsaturated.

14. The compound of claim 1 , wherein

n is 1 or 2;

X is O or NH;

Y is an aromatic ring optionally substituted with methoxy or fluorine; and

Z is C 1-10 alkyl-O—, wherein said alkyl is saturated or unsaturated.

15. A compound selected from the group consisting of:

16. A compound according to claim 1 selected from the group consisting of:

17. A pharmaceutical composition comprising a compound of claim 1 or a pharmaceutically acceptable salt or solvate thereof, and one or more pharmaceutically acceptable carriers.

18. A pharmaceutical composition comprising a compound of claim 15 or a pharmaceutically acceptable salt or solvate thereof, and one or more pharmaceutically acceptable carriers.

19. A method of treating a viral infection comprising administering a therapeutically effective amount of at least one compound of claim 1 .

20. A method of treating a viral infection comprising administering the pharmaceutical composition of claim 17 .